Home › Respiratory Tract Infections › NCT05474430
Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity
Estimating the Risk for and Severity of Respiratory Infections Attributable to CFTR Heterozygosity
Who can join
Ages 18 to 100 · All sexes
Full eligibility criteria
CF Carrier Inclusion Criteria: * Previously tested and shown to be a CF carrier * English-speaking Control Group Inclusion Criteria: * Previously tested and shown to not be a CF carrier or CF patient * English-speaking Exclusion Criteria: * Currently sick with a respiratory infection * Prisoner Status * Unable to provide own written, informed consent
About the study
A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays.
An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19.
The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.
Sponsor: Philip Polgreen · Participants: 160 · Started: Dec 20, 2021
Contact the study team
- Philip M Polgreen, MD · Phone: (319) 384-6194
- Shelby L Francis, PhD · Phone: 319-678-8037
Official record on ClinicalTrials.gov — NCT05474430
Locations in the U.S.
| Iowa | University of Iowa Hospitals and Clinics, Iowa City |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.